Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| fibroblast | 11 studies | 25% ± 7% | |
| adipocyte | 9 studies | 54% ± 12% | |
| alveolar macrophage | 8 studies | 29% ± 6% | |
| podocyte | 5 studies | 55% ± 20% | |
| mesothelial cell | 5 studies | 30% ± 13% | |
| adventitial cell | 4 studies | 34% ± 1% | |
| placental villous trophoblast | 3 studies | 34% ± 8% | |
| connective tissue cell | 3 studies | 38% ± 14% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| adipose | 3 studies | 28% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 85% | 2644.15 | 208 / 245 | 89% | 9.82 | 449 / 502 |
| kidney | 80% | 2091.47 | 71 / 89 | 73% | 24.62 | 659 / 901 |
| bladder | 90% | 3757.14 | 19 / 21 | 36% | 3.41 | 182 / 504 |
| breast | 80% | 3997.83 | 369 / 459 | 45% | 5.29 | 503 / 1118 |
| lung | 57% | 832.23 | 329 / 578 | 64% | 7.65 | 740 / 1155 |
| esophagus | 67% | 2090.13 | 964 / 1445 | 43% | 3.13 | 79 / 183 |
| liver | 21% | 217.73 | 48 / 226 | 81% | 19.05 | 330 / 406 |
| blood vessel | 99% | 7057.71 | 1325 / 1335 | 0% | 0 | 0 / 0 |
| heart | 99% | 8074.52 | 853 / 861 | 0% | 0 | 0 / 0 |
| adipose | 99% | 6198.64 | 1186 / 1204 | 0% | 0 | 0 / 0 |
| skin | 27% | 361.76 | 481 / 1809 | 58% | 6.67 | 273 / 472 |
| uterus | 34% | 683.45 | 58 / 170 | 49% | 6.34 | 223 / 459 |
| thymus | 43% | 763.07 | 278 / 653 | 26% | 1.83 | 157 / 605 |
| brain | 1% | 7.19 | 18 / 2642 | 68% | 6.79 | 476 / 705 |
| pancreas | 0% | 0 | 0 / 328 | 63% | 4.30 | 112 / 178 |
| tonsil | 0% | 0 | 0 / 0 | 62% | 5.86 | 28 / 45 |
| intestine | 37% | 592.08 | 362 / 966 | 19% | 1.49 | 101 / 527 |
| ovary | 14% | 166.02 | 25 / 180 | 32% | 1.52 | 138 / 430 |
| stomach | 21% | 324.49 | 76 / 359 | 22% | 1.22 | 62 / 286 |
| eye | 0% | 0 | 0 / 0 | 39% | 1.66 | 31 / 80 |
| adrenal gland | 4% | 38.45 | 11 / 258 | 33% | 6.73 | 75 / 230 |
| lymph node | 0% | 0 | 0 / 0 | 31% | 1.91 | 9 / 29 |
| peripheral blood | 10% | 148.72 | 90 / 929 | 0% | 0 | 0 / 0 |
| muscle | 6% | 85.29 | 49 / 803 | 0% | 0 | 0 / 0 |
| spleen | 6% | 54.44 | 14 / 241 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_1990830 | Biological process | cellular response to leukemia inhibitory factor |
| GO_0005576 | Cellular component | extracellular region |
| GO_0008201 | Molecular function | heparin binding |
| GO_0005518 | Molecular function | collagen binding |
| GO_0016504 | Molecular function | peptidase activator activity |
| Gene name | PCOLCE2 |
| Protein name | Procollagen C-endopeptidase enhancer 2 (Procollagen COOH-terminal proteinase enhancer 2) (PCPE-2) (Procollagen C-proteinase enhancer 2) Procollagen C-endopeptidase enhancer 2 Alternative protein PCOLCE2 |
| Synonyms | UNQ250/PRO287 PCPE2 |
| Description | FUNCTION: Binds to the C-terminal propeptide of types I and II procollagens and may enhance the cleavage of that propeptide by BMP1. . |
| Accessions | L8E804 Q9UKZ9 ENST00000485766.1 H7C520 ENST00000470310.5 A0A3B3ITE8 ENST00000648195.1 C9JYX9 ENST00000295992.8 ENST00000480473.5 H7C5D5 |
